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ABSTRACT

The invention involves methods and compositions useful in

delivering micronutrients to cells. By formulating the micro
nutrient in the form of an ester that is convertible to the
active form of the micronutrient, one can combine it With a
co-ester that inhibits esterases, so that the micronutrient can

Prior Publication Data
US 2002/0037898 A1 Mar. 28, 2002

reach the targeted cells prior to degradation. Both methods
Related US. Application Data
(60)

and compositions are described.

Provisional application No. 60/197,828, ?led on Apr. 14,

48 Claims, 3 Drawing Sheets

2000.

\

A Pronutrient rapidly partitions from a skin

%

cream or lotion into the surface layer of skin \% 1
)

Thefrom
Pronutrient
the surface
partitions
layer into
at athe
Controlled
epidermis
rate

/

The Pro-Compound is bioconverted
at a controlled rate into a bioactive compound

by enzymes present in the epidermis

i/Q/J

l

'

/ degree/QM
/

WW”

?mQ;

a

firth

j

Tl

Stratum Corneum

(Dead Cells, Lipid Rich)

Epidermis

(Live Dividing Cells)
Dermis
(Cells and Non-cellular

The bioactive compound is delivered to the
desired location to allow its biological effect in:

Matrix Protein Fibers Such

as Collagen and Elastin)

skin cells in epidermis
skin cells in dermis

cells in blood Capillaries

YR

} ( routeBlood
Capillaries
to general circulation)
/

U.S. Patent

Oct . 15,2002

Sheet 2 0f 3

US 6,464,992 B2

Donor Compartment
or Formulated

Nutrient <———— Pronutrient

Cream/Lotion

#2

______________ __r #1 _-_-_

Stratum

Comeum

Nutrient

Pronutrient

_'_'__": '''''''''''''''''''''''''''' '_ —

Epldermls

#3 —'_'_

#4
Nutrient

<———— Pronutrient

/
Keratinocytes

/

/
Nutrient

/

#6 T //
Pronutrient

Dermls

V

#5

y

Nutrient <——— Pronutrient

/
Fibroblasts

/

/
Nutrient

#7 T

//
/’

Pronutrient

Blood

Capillaries

ll

Nutrlent

FIG. 2

US 6,464,992 B2
1

2

TOPICAL MICRONUTRIENT DELIVERY
SYSTEM AND USES THEREOF

exposed to ROS during the normal course of energy
metabolism, via environmental exposure and/or immune
surveillance. While ROS are involved in normal cell signal

ing pathWays, elevation of ROS during oxidative stress

PRIORITY CLAIM

disrupts signaling pathWays, often resulting in cell death by

This application claims priority to provisional application
No. 60/197,828 ?led Apr. 14, 2000, incorporated by refer

apoptosis or necrosis. Thus, it is likely that ROS are
involved in the loss of cell numbers observed even in
sun-protected skin over time. Exposure to the ultraviolet
rays of sunlight is a major source of skin oxidative stress.

ence in its entirety.
FIELD OF THE INVENTION
10

TWo major targets for damage by ROS in skin are DNA and
protein. DNA damage is of particular interest in that unre

This invention relates to a topical micronutrient delivery

paired damage can lead to the loss of skin cells and to an

system. The system is useful in, e.g., delivery of desirable

altered function of cells that survive genotoxic stress.
While some changes in skin during aging can not be

and/or necessary materials, such as micronutrients, to a
subject in need of same. Therapeutic uses of the system are
also described.

avoided, much of the skin deterioration that occurs at an
15

BACKGROUND AND PRIOR ART

damage to DNA and proteins caused by ROS. First, a
the antioxidant vitamins C and E, play key roles in scav
enging ROS before they can react With cellular macromol

mental insults. Environmental exposure results in the pro
20

can lead to end stage diseases such as actinic keratosis and
skin cancer.

complex mechanisms for the maintenance of genomic integ
rity. Of particular interest herein is the accumulating evi
25

age.
35

mended daily intake see Wilson, et al. Data Tables: Com
bined Results from USDA’s 1994 and 1995 continuing
survey of food intakes by individuals and 1994 and 1995 diet

and health knoWledge survey (USDA/ARS Food Surveys
Research Group, Beltsville Human Nutrition Research

Center, Riverdale, Md. (1997), incorporated by reference.
40

keratinocytes are the major cell type. Dermal ?broblasts are

The percentage of the US. population that is de?cient in a
particular micronutrient ranges from 2 to 20%. Ames, supra.
To complicate matters, micronutrient status deteriorates fur

ther With increasing age. Bates, et al., Br. J. Nutr 82(1):7—15
(1999). Much of our knoWledge about the relationship

embedded Within a matrix comprised of collagen, elastin,
proteoglycans, and other extracellular matrix molecules.
Blood capillaries are found in the dermis, but the epidermis
is non-vascular.

reference). For many of these micronutrients, a siZeable
portion of the population consumes signi?cantly less of the
micronutrient than What has been established as the recom

advanced societies and micronutrient status decreases With

protective barrier for the underlying components of skin.
The epidermis contains a number of cell types, although

dence for the involvement of micronutrients in maintenance
of DNA structure and in DNA repair mechanisms. There are
approximately 40 micronutrients that are required, in small
amounts, to maintain normal human metabolism (Ames,

Ann. NY. Acad. Sci 889: 87—106 (1999), incorporated by
30

Sub-clinical micronutrient de?ciencies are prevalent even in

Skin is a complex organ system, consisting of multiple
layers. The uppermost, or “stratum corneum” layer consists
of non-living material derived primarily from the terminal
differentiation of epidermal keratinocytes, and provides a

ecules. Indeed, the antioxidant vitamins have already found
application in the prevention of skin deterioration, as they
are components of many skin creams. Second, cells contain

Skin deterioration results from damage to DNA and

protein, and compelling evidence indicates that reactive
oxygen species (“ROS” hereafter) are involved in the gen
eration of DNA damage that results in the loss of genomic
integrity of skin cells. Skin cells contain inherent mecha
nisms for the maintenance of genomic integrity. A groWing
body of evidence demonstrates that micronutrients including
vitamins B6, B12, C, E, folate, and niacin are involved in the
maintenance of genomic integrity via mechanisms ranging
from scavenging ROS, to the repair of DNA damage.

protective mechanisms for the prevention and repair of

number of intracellular molecules, including glutathione and

The skin plays multiple roles in protection from environ
gressive deterioration of skin that is initially cosmetic but

early age is avoidable. Skin cells contain a number of

betWeen micronutrients and various diseases such as cancer

derives from measurements of micronutrient levels in
45

As people age, progressively deleterious changes in skin

plasma. While there is much to learn regarding plasma
micronutrient levels and target tissue levels, there is evi

appearance occur. The initial changes are the loss of smooth

dence that de?ciencies observed in plasma are also observed

skin texture and the appearance of age spots, folloWed by
changes in elasticity that lead to the appearance of skin
Wrinkles. The age at Which these changes appear and the rate

in skin. See Peng, et al., Canc. Epidermiol Biomarkers Prev

2(2): 145—50 (1993). This is not surprising, since the epi
50

at Which one stage progresses to the next varies greatly from

individual to individual. During the normal aging process,
both the epidermis and dermis become thinner, With a loss
of cell number and connective tissue, leading to the appear
ance of ?ne Wrinkles. Ultraviolet (UV) irradiation from the
sun causes photodamage that accelerates skin deterioration.

dermal layer of skin does not contain blood vessels, making
delivery of dietary micronutrients to skin inef?cient. Of
particular concern for skin deterioration are observations
that micronutrient de?ciencies can mimic radiation- and

chemical-induced DNA damage, by effecting single-and
55

double-strand breaks and/or oxidative lesions. Ames, supra.

Speci?cally, de?ciencies in folic acid, B12, B6, niacin,

In contrast to the thinning observed in sun-protected skin,
photodamaged skin has a thickened and rough appearance
With an increase in deeper skin Wrinkling. Photodamage also

vitamin C, vitamin E, iron, and Zinc can result in DNA

causes end-stage skin deterioration, including pre-malignant

nale by Which a de?ciency results in DNA damage in the
absence of genotoxic stress. Additionally, the micronutrient
de?ciencies Would be expected to exacerbate the deleterious
effects of genotoxic stress. The above information indicates
that improving the micronutrient status of skin cells is
desirable, as this Will improve the health of skin and likely
retard skin deterioration.
It is an object of the invention to provide a tropical
delivery system Which is useful in making micronutrients

lesions termed actinic keratosis, and skin cancer.
Compelling evidence noW indicates that oxidative stress,
de?ned as an abnormal accumulation of ROS, is involved in

damage. Ames, supra. For each of these micronutrients,
there are knoWn metabolic pathWays that describe the ratio
60

the pathophysiology of skin deterioration. ROS include

superoxides, the hydroxyl radical, hydrogen peroxide, sin
glet oxygen, nitric oxide, peroxynitrite, and hypochlorite.
See, e.g., Simonian, et al., Ann. Rev. Pharmacol. Toxicol.
36:83—106 (1996), incorporated by reference. All cells are

65
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available, or making these micronutrients available in

octanol/Water partition coefficient (Pod/W) are of value in
predicting drug transport across skin. A linear correlation

greater quantities than possible in the past.

betWeen skin permeability (Log PB) of many compounds

It is a further object of the invention to arrest or to prevent

and their logarithm of Pod/W has been established and is Well

deterioration of organs such as skin, by making micronutri

knoW in the art. Deviations from this relationship are

ents available in amounts sufficient to arrest or to prevent the

observed for very hydrophilic and extremely lipophilic

deterioration.
HoW this is accomplished Will be seen from the disclosure
Which folloWs.
BRIEF DESCRIPTION OF THE DRAWINGS

compounds. Compounds With optimal lipophilicity for
delivery of a micronutrient to the cellular components of
skin are disclosed herein. For niacin, e.g., as the model
micronutrient, a series of alkyl esters of niacin Were pre
10

FIG. 1 depicts the skin, in cross section, in combination
With an illustration of the delivery system of the invention.

of niacin (NAD) folloWing topical application thereof, using

FIG. 2 elaborates an embodiment of the invention.

FIG. 3 outlines the results of an experiment designed to

determine the efficacy of co-esters in modulating delivery of

pared and their relative lipophilicity Was determined. Next,
the efficacy of these pronutrients in delivering niacin to the
cellular components of skin by measuring the bioactive form
established models.

15

It is believed that short chain esters may have an intrinsic
?ux from the stratum corneum that is too rapid for sustained

delivery to skin, i.e., systemic delivery Will be favored.

active compounds.

LikeWise, a very long chain derivative is predicted to have
DETAILED DESCRIPTION OF PREFERRED
EMBODIMENTS

a lipophilicity that Will have an intrinsic ?ux that is too sloW
for effective delivery. The lipophilicity of a number of neW
niacin esters disclosed in Ser. No. 09/452,617, along With
some commercially available esters is shoWn in Table 1

The topical delivery system of the invention takes into
consideration the tWo distinct barriers that in?uence the

delivery of micronutrients to skin, i.e., the lipophilicity of
stratum corneum, and skin metabolic activity. The micro
nutrient delivery system of the invention is outlined in FIG.
1. In brief, the partitioning of the micronutrient in and out of
the stratum corneum is controlled by the nutrient esters With

25

also shoWs that nicotinic acid and niacin esters With log P
values of less than 6 cause vasodilation at the site of topical

optimal lipophilicity for such partitioning. These are
described, infra. The term “pronutrient” is used to describe
these compounds. Further, the rate and site of inetabolic
conversion of pronutrients is controlled by the use of inac
tive companion co-esters as described infra. Several features
are required for this delivery system to function optimally.
FIG. 2 shows a multiple compartment model that served as
the frameWork for the development of these criteria. The
model micronutrient used is niacin, but the skilled artisan

infra, together With values for the tWo, unmodi?ed
molecules, i.e., nicotinic acid and nicotinamide. The lipo
philicity is reported as log P values, Where P refers to the
octanol/Water partition coefficient, described supra. Table 1
application. This demonstrates that these nicotinic acid and
niacin esters are delivering niacin at a rate that exceeds the
minimum concentration needed to cause vasodilation of the

35

Will realiZe that the information disclosed is relevant to a
Wide variety of micronutrients as described in more detail

endothelial cells of the blood capillaries. Niacin esters With
log P values greater than 6 do not cause dilation. Nicotina
mide does not cause vasodilation, but its log P value also
predicts that it Will deliver nutrient too rapidly to alloW the
cellular components of skin to assimilate it and convert it to

its bioactive form NAD. To determine the optimum physical
properties of pronutrient for topical delivery to the cells of
the skin, niacin esters With log P values ranging from 6.6 to
9.2 Were examined by determination of the active form of
niacin, NAD in the skin folloWing application of the lotion.
Results from a typical experiment are shoWn in Table 2,
Where niacin pronutrients formulated at 1% Were topically

infra.
The highly lipophilic nature of the stratum corneum
dictates that the desired micronutrient must be sufficiently
lipophilic to effectively partition into the stratum corneum
from the donor compartment, Which may be a skin cream or

lotion (#1 in FIG. 2). This necessitates the preparation of
distinct lipophilic pronutrients, as most micronutrients of
interest are too hydrophilic to meet this criterion. As 45

described in more detail infra, the required lipophilicity
needed for diffusion from the stratum corneum into the

epidermis predict that ef?cacious pronutrients should be

applied to the backs of hairless mice once a per day for three
days. After three days, skin Was removed from both the site
of application and from the abdomen of each animal, and the
NAD content Was analyZed. Analysis of skin from the backs
of the animals demonstrated that niacin esters of 12, 14, and
16 carbons resulted in an increased NAD content, although
the 14 carbon ester Was the most effective. In further
experiments, it Was determined that a niacin ester With a

sufficiently lipophilic to rapidly partition from the cream or
lotion into the stratum corneum. Esters of micronutrients are

carbon side chain of 18, and a log P value of 9.7 Was less
effective that the ester With a 16 carbon side chain. Further,

used herein, as this alloWs lipophilic derivatives to be
prepared and also alloWs their efficient bioconversion fol
loWing diffusion out of the stratum corneum into the epi
dermis.
The lipophilicity of the pronutrients should alloW them to
be formulated in, e.g., skin creams or lotions, and the ester
linkages should be very stable in these formulations.
Although the non-derivatiZed micronutrient Would be
expected to partition very sloWly into the stratum corneum

it Was shoWn that topical application of niccotinamide,
Which has a log P value of —0.34, had no effect on skin cell
NAD content. The results of Table 2 also shoW that the
delivery Was topical for the 14 and 16 carbon esters, as there
Was no increase in the NAD content of the abdomen Where

the pronutrient Was not applied. Topical application of the 12
carbon ester did shoW some delivery to the abdomen, Which

is consistent With the suggestion, supra that this compound
should have the fastest rate of delivery of the compounds

(#2 in FIG. 2), a pronutrient that is very stable is high

compared in this experiment.

desirable. The esters disclosed herein are pronutrients that
are stable to chemical hydrolysis under aqueous conditions,
as Well When formulated in a cream or lotion.

The delivery approach disclosed herein involves the bio
conversion of the pronutrient to the desired micronutrient by

The pronutrient must partition into the epidermis at a
relatively sloW rate to achieve sustained delivery to the

the action of skin esterases. Studies on the esterase distri
bution of skin have shoWn that the stratum corneum has little

cellular components of skin With minimal systemic delivery

(#3 in FIG. 2). Acorrelation betWeen skin permeability (PB)
and the physicochemical properties of the drug, such as

65

or no activity, the epidermis has the highest activity and the
dermis has reduced activity relative to the epidermis. See
Sugibayashi, et al. J. Controlled Release 62:201—208 (1999)

US 6,464,992 B2
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incorporated by reference. Delivery should be possible

experiment, the eight carbon ester of niacin (octyl
nicotinate) for delivery of niacin to the endothelial cells of

Whether the bioconversion is extracellular (#4 & 5, FIG. 2)
or following uptake by the target cells (#6 & 7 in FIG. 2) as
cells contain speci?c transport systems for micronutrients
and the lipophilicity of the pronutrients should make them
readily bioavailable via passive diffusion. Since the stratum

blood capillaries, in order to increase the oxygen content of
skin. In this experiment, a transcutaneous oxygen monitor
has been used to determine oxygen content in the skin. A

corneum contains little or no esterase activity, the rate of

for thirty minutes. The lotion Was then removed and the

disappearance of a pronutrient from the stratum corneum
depends only on the rate of diffusion, Which can be
described by Fick’s second laW of diffusion:

lotion containing the test compound Was topically applied
transcutaneous oxygen monitor Was placed on the surface of
10

the skin. The control experiment shoWed that the oxygen
content of skin (P02) shoWs a value of 4 mm, demonstrating
the relatively loW oxygen content Was increased. The dura
tion of the increase is not long because the lotion must be
removed in order to make the oxygen measurement. Butyl

Where dc/dt is the change in pronutrient concentration over
time, CSC is the pronutrient concentration in the stratum

benZoate Was chosen as the co-ester. Butyl benZoate has a
corneum and D SC is the diffusion coef?cient from the 15 log P value of 3.5 compared to a log P value of 4.8 for octyl

stratum corneum.

nicotinate. FIG. 3 shoWs that a formulation containing both

In the epidermis and dermis, Where both diffusion and
metabolism are occurring simultaneously, both diffusion and

octyl nicotinate and butyl benZoate blocked the increase in
skin oxygen content elicited by octyl nicotinate alone,

metabolism must be considered. Thus the rate of disappear
ance from these compartments can be described by:

demonstrating modulation of delivery of the pronutrient by
20

The experiments Which folloW set forth the invention in
greater detail, but should not be construed as limiting the
invention in any Way.

dCproN/dt=DproNd2CproN/d2x_ Vm1l>c(x) 'CproN/Km +CproN
Where CpmN and DPrON are the concentration and diffusion
co-ef?cient of the pronutrient in the epidermis or dermis and
Vmax(x) is maximum rate of metabolic conversion at posi

25

tion X, and Km is the Michaelis-Menten constant.
The use of ester derivatives of micronutrients is appli

Ser. No. 09/452,617, ?led Dec. 1, 1999, incorporated by

presented in Table 3. The micronutrients shoWn contain

reference. In brief, nicotinoyl chloride Was combined With
30

With an alcohol functionality can be esteri?ed to a long chain
35

inactive co-esters, as these alloW modulation of nutrient

delivery to speci?c locations Within skin. The high esterase
content in the epidermis favors the delivery of topically
applied pronutrients to cells present in the epidermis. While
delivery to cells in the epidermis is a major goal of the
topical delivery system, it is also highly desirable to achieve

triethylamine (TEA), dimethylaminopyridine (DMAP), and
various alkyl alcohols, under nitrogen. Esters resulting from

desired lipophilicity for topical delivery. Micronutrients
acid to achieve the desired lipophilicity.
It is preferred to combine the esters described supra, With

EXAMPLE 1

Nicotinic acid esters Were synthesiZed in accordance With

cable to a Wide range of micronutrients, some of Which are

either an acid functionality, an alcohol functionality, or both.
Micronutrients containing an acid functional group can be
esteri?ed to a long chain alcohol to alloW formation of the

the co-ester.

the synthesis Were separated via silica gel column
chromatography, and converted to HCl salts for further
puri?cation, using standard methods. The purity Was con
?rmed via thin layer chromatography, and 1H-NMR.
The Pact/W values for these compounds Were determined in
accordance With Harnisch, et al., J. Chromatog.

282:315—332 (1983), incorporated by reference. In brief,
40

this HPLC method determines capacity factor (“K‘”) for
each pronutrient, and also establishes a linear relationship

betWeen the logarithm of Pact/W and the logarithm of K‘, for
short chain pronutrients. Rate of hydrolysis of candidate

delivery to dermal ?broblasts and to endothelial cells in

blood capillaries in the skin. Enhancing delivery to the

nicotinic acid ester derivatives Was determined, in aqueous

dermis and blood capillaries can be achieved by the use of
inactive co-esters that can be used to modulate the extent of 45

phosphate buffer, at physiological pH (7.4), With incubation

bioconversion of pronutrients in the epidermis. For co-esters

at 37° C. Rate of pronutrient disappearance from solution

to modulate the rate of conversion of pronutrients in the
skin, tWo criteria must be met. First, the co-ester must have
lipophilicity similar to that of the pronutrient, such that ?ux
from the stratum corneum of the pronutrient and co-ester is
similar. Second, the co-ester must effectively compete With
the pronutrient for bioconversion by the skin esterases. At

Was monitored, by HPLC, at 254 nm.
EXAMPLE 2
50

In animal experiments, female hairless mice (HRS-J, 6—8

Weeks old), received daily topical application of nicotinic

concentrations of pronutrient beloW enZyme saturation,
co-esters Will competitively inhibit the metabolic conversion

in the epidermis (#4 in FIG. 2) and alloW the pronutrient to
pass intact to the dermis (#5 in FIG. 2) for conversion and

55

delivery. This approach minimiZes the required dose of
pronutrients and provides a good targeted delivery system to
the dermis. The targets of delivery in the dermis include both
dermal ?broblasts and capillary endothelial cells. For the
dermal ?broblasts, the aim is to deliver niacin for conversion
to AND. For the capillary endothelial cells, the knoWn
vasodilation properties of niacin may be useful for increas

Animals Were euthaniZed, and dorsal and ventral skin
60

samples Were then froZen in liquid nitrogen, and stored at
—80° C. In order to analyZe NAD and protein content, tissue
samples Were homogeniZed, in 0.5M, ice cold HClO4, and
then centrifuged at 3000 rpm for 15 minutes. The resulting
supernatants Were neutraliZed With ice-cold 2M KOH/
0.66M KH2PO4, in order to determine NAD. The NAD Was

ing blood How in the dermis, increasing the supply of
oxygen and other essential nutrients and increasing the
ef?ciency of removal of carbon dioxide and other metabolic
end products. An experiment demonstrating the use of
co-esters to modulate delivery is shoWn in FIG. 3. For this

acid esters, using 200 mg of commercially available “Vani
cream” lotion, at a 1.0% (Wt/Wt) concentration, for three
days. Control animals received Vanicream only. The lotions
Were applied, daily, for one Week.

determined in accordance With Jacobson, et al., Meth. EnZy
65

mol. 280: 221—230 (1997) incorporated by reference, While
a commercially available BCA method Was used for protein
determination.

US 6,464,992 B2
8
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ranging from about 6.5 to about 8.5, more preferably from
TABLE 1

about 7.0 to about 8.0. As Was shoWn in the examples set
forth herein, in the case of the niacin esters, a log P of about

Properties of Niacin Pronutrients

7.6 Was ideal. For niacin this resulted from an ester With a

14 carbon side chain. It Will be understood by the skilled
Alkyl Carbon Chain Length
Nicotinamide (NO Side Chain)
Nicotinic Acid (No side chain)
1 Carbon
2 carbons
4 carbons
6 carbons

Log P Value Erythematous Response
_O_34
NO
-0_46
Yes
0-84
Yes
1-3
Yes
2.4
Yes
35
Yes

8 carbons
10 carbons

48
58

Yes
Slight

12 carbons

6-6

NO

13 carbons

7'5

N0

i;

g

10

artisan that the preferred structures Will vary from nutrient to
nutrient or micronutrient to micronutrient, but the log P
values Will control. The computation of log P values should
be carried out as described herein. The log P values recited
herein are predictive of the rate of partitioning of the
~
~
~
~
~
~
~
materials of interest. Many micronutrients of interest exist in
esteri?ed form. Processes for esterifymg others are knoWn to
the art, and need not be set forth here.
As indicated, supra, it is preferred that the micronutrient
of interest be combined With a “co-ester.” This co-ester, as

15 used herein, refers to a compound Which is an ester, and is

16 carbons

92

NO

less lipophilic than the micronutrient, so that it Will migrate

18 carbons

9.7

No

slightly faster from, e.g., the stratum corneum so as to

occupy esterases, such as skin esterases, thereby permitting
diffusion of the micronutrient into the loWer layers of the
TABLE 2
Skin NAD content following topical application
of niacin pronutrients
Skin NAD content of back

Alkyl Group

Log P

Lotion only
12 Carbons
14 Carbons
16 Carbons

—
6.6
7.6
9.2

pmol NAD/mg tissue
91.4
129.4
165.7
109.5

+/+/+/+/-

18.4
15.4
12.0
8.3

Skin NAD content of abdomen

%

pmol NAD/mg tissue

100
141
181
120

60.4
82.6
55.8
52.1

+/+/+/+/-

15.2
14.8
13.8
10.4

%
100
137
92
86

skin. In quantitative terms, it is preferred that the lipophi
TABLE 3

35 licity of the co-ester should be Within a factor of about 20,
i.e., have a log P Which differs from the value for the

Micronutrient Candidates for Generation of Pronutrient Esters

micronutrient With Which it is coadministered or formulated

by from about 0.5 to about 1.5, preferably by about 1.0 to
Contain Alcohol Group

Contain Carboxylic Acid Group

Vitamin B6
Folic Acid

Niacin
Folic Acid

about 1_5_
40

Formulations as described above are covered by the
invention, as are methods for delivering a micronutrient to

Vitamin B12

Lipoic Acid

a subject, via administering a combination of the micronu

Pantothenic acid

Pantothenic acid

trient and the co-ester, in an amount sufficient to facilitate

Carnitine

Carnitine

Ribf’?fivin

Ublqumones

The foregoing sets forth the features of the invention,
Which relates, inter alia, to systems and methods for delivery
of nutrients, such as micronutrients, to a subject. Preferably,

these are topical delivery systems, in that they are formulated for administration in the same manner as are other
topical formulations. In addition to creams and lotions,

topical formulations Such as Shampoos, liquids Such as eye

delivery of said micronutrient. In practice, the delivery
system described herein can be administered to a site of

45 injury, thus being used therapeutically, and/or it can be
administered prophylactically, i.e., prior to exposure of the
5km and/Or Organ to lhsuh’ gehotoxlc Stress’ 6t?‘ The for'
mulahohs can .be prepared Such that they Vary 1h Strength‘
The cohcehtrahoh Should range from about 0'005% to about
50 50%’ more preferably from about 0'005% to 25%’ and
mOStPrefGrabIY from abpht 001% to abOut1'0% by Welght
of Sald apphed composlhoh' _

_

_

'Other features of the invention Wlll be clear to the skilled

Washes, balms and sticks such as lip balms and deodorant
amsan and need not be Set forth hereln
sticks, mouthWashes and gavages, soaps, suppositories, 55
The terms and expressions Which have been employed are

patches, bandages, suturing threads, coated implant devices,

used as terms of description and not of limitation, and there

and any other type of system designed for topical application
are a part of the invention. Preferably, the formulation is
designed for application to, e.g., skin or other organs, such
as liver, lungs, stomach, etc., scalp, eyes, blood vessels, and

is no intention in the use of such terms and expressions of
excluding any equivalents of the features shoWn and
described or portions thereof, it being recognized that vari
ous modi?cations are possible Within the scope of the

so forth.

6O invention.

The micronutrient used in the formulations may be any of
those referred to by Ames, et al., supra, such as those set out
in table 3. Preferably, the micronutrient is one Which con-

We claim:
1. A method for delivering a nutrient to a subject, com
prising topically applying to said subject a composition

tains an acid moiety (e.g., ascorbic acid), an alcohol moiety,

Which comprises said nutrient, in the form of an ester, and

or both. It is also preferred that the alcohol moiety or 65 a co-ester Which inhibits esterases and is less lipophilic than
moieties of the micronutrient be in esteri?ed form. These
the ester form of said micronutrient, in an amount sufficient
esteri?ed forms of micronutrients should have a log P value
to facilitate delivery of said nutrient to cells of said subject.

US 6,464,992 B2
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26. The composition of claim 25, Wherein said niacin is in

2. The method of claim 1, wherein said nutrient is a
micronutrient.
3. The method of claim 2, Wherein said micronutrient is

the form of an ester having an alkyl side chain of from 12—16
carbon atoms.

27. The composition of claim 26, Wherein said alkyl side

a micronutrient Which contains an alcohol group.

chain consists of 14 carbon atoms.

4. The method of claim 3, Wherein said micronutrient is

28. The composition of claim 18, Wherein said co-ester is

vitamin B6, folic acid, vitamin B12, pantothenic acid,

benZyl benZoate.

carnitine, ribo?avin or an ubiquinone.

29. The composition of claim 18, Wherein and (ii) have
log P values Which differ from each other by about 1.3.
30. The composition of claim 18, Wherein
has a log P

5. The method of claim 2, Wherein said micronutrient is
a micronutrient Which contains a carboXylic acid group.

6. The method of claim 5, Wherein said micronutrient is

ascorbic acid, niacin, folic acid, lipoic acid, pantothenic

1O

suffering from de?ciency of said nutrient comprising topi
cally applying to said subject a composition Which com
prises said nutrient, in the form of an ester, and a co-ester
Which inhibits esterases, in an amount su?icient to facilitate

delivery of said nutrient to cells of said subject.
33. The method of claim 32, Wherein said nutrient is a
micronutrient.
34. The method of claim 33, Wherein said micronutrient

lipophilicity log P value Which differs from said micronu
trient from about 0.5 to about 1.5.
11. The method of claim 1, Wherein said ester and co-ester

is a micronutrient Which contains an alcohol group.

35. The method of claim 34, Wherein said micronutrient

have log P values Which differ from each other by about 1.3.
12. The method of claim 1, Wherein said ester has a log

is vitamin B6, folic acid, vitamin B12, pantothenic acid,
carnitine, ribo?avin or an ubiquinone.
25

37. The method of claim 36, Wherein said micronutrient

is ascorbic acid, niacin, folic acid, lipoic acid, pantothenic

in the form of a cream, a lotion, a shampoo, an eye Wash, a
balm, a stick, a mouthWash, a gavage, a soap, a suppository,
a bandage, a suturing thread or an implant device.

acid, or carnitine.

15. The method of claim 1, Wherein said subject suffers
from a de?ciency of said micronutrient.

16. The method of claim 15, comprising administering
35

lipophilicity log P value Which differs from said micronu
co-ester have log P values Which differ from each other by

20. The composition of claim 18, in a form suitable for

21. The composition of claim 19, Wherein said micronu

45

trient contains an alcohol group.

22. The composition of claim 19, Wherein said micronu

in the form of a cream, a lotion, a shampoo, an eye Wash, a
balm, a stick, a mouthWash, a gavage, a soap, a suppository,
a bandage, a suturing thread or an implant device.

23. The composition of claim 21, Wherein said micronu
trient is vitamin B6, folic acid vitamin B12, pantothenic
acid, carnitine, ribo?avin, or an ubiquinone.
24. The composition of claim 22, Wherein said micronu

47. The method of claim 32, comprising administering

trient is ascorbic acid, niacin, folic acid, lipoic acid, pan
tothenic acid, or carnitine.

25. The composition of claim 24, Wherein said micronu

about 1.3.
44. The method of claim 32, Wherein said ester has a log
P value of from about 6.5 to about 8.5.
45. The method of claim 44, Wherein said ester has a log
P value of from about 7 to about 8.

46. The method of claim 32, Wherein said composition is

trient contains a carboXylic acid group.

trient is niacin.

38. The method of claim 37, Wherein said micronutrient
is niacin.
39. The method of claim 38, Wherein said niacin is
administered in the form of an ester having an alkyl side
chain of from 12—16 carbon atoms.
40. The method of claim 39, Wherein said alkyl side chain
consists of 14 carbon atoms.
41. The method of claim 32, Wherein said co-ester is less
liphophilic than the ester form of said micronutrient.
42. The method of claim 41, Wherein said co-ester has a
trient from about 0.5 to about 1.5.
43. The method of claim 32, Wherein said ester and

a micronutrient.

topical administration.

36. The method of claim 33, Wherein said micronutrient
is a micronutrient Which contains a carboXylic acid group.

14. The method of claim 1, Wherein said composition is

said composition to a site of injury on said subject.
17. The method of claim 1, Wherein said co-ester is butyl
benZoate.
18. Composition useful in delivering a nutrient to a
subject, comprising:
an esteri?ed form of said nutrient
and (ii) a co-ester Which inhibits esterases Wherein said
co-ester is less lipophilic than the esteri?ed form of said
nutrient.
19. The composition of claim 18, Wherein said nutrient is

has a log P

value of from about 7 to about 8.
32. A method for delivering a nutrient to a subject

7. The method of claim 6, Wherein said micronutrient is
niacin.
8. The method of claim 7, Wherein said niacin is admin
istered in the form of an ester having an alkyl side chain of
from 12—16 carbon atoms.
9. The method of claim 8, Wherein said alkyl side chain
consists of 14 carbon atoms.
10. The method of claim 1, Wherein said co-ester has a

P value of from about 6.5 to about 8.5.
13. The method of claim 12, Wherein said ester has a log
P value of from about 7 to about 8.

value of from about 6.5 to about 8.5.

31. The composition of claim 18, Wherein

acid, or carnitine.
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said composition to a site of injury on said subject.
48. The method of claim 32, Wherein said co-ester is butyl
benZoate.
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